The present invention relates to the use of ferroquine, the N-demethylated metabolite or any of the pharmaceutically acceptable salts thereof for treating and/or preventing infections caused by a parasite belonging to the Plasmodium genus, the life cycle of which includes a phase of hepatic latency in the human host.